
Biomednewsbreaks Clene Inc. (NASDAQ: CLNN) Advances Regulatory Strategy For CNM-Au8 With FDA Meetings Scheduled For ALS ...
(MENAFN- Investor Brand Network) Clene (NASDAQ: CLNN) announced key regulatory developments following a Type C meeting with the FDA, where it received feedback on its statistical analysis plan (SAP) for evaluating neurofilament light (NfL) biomarker data …